Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Key market opportunities for abemaciclib include growing demand for targeted therapies in oncology, advancements in ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

On December 3, Guggenheim raised its price target on Eli Lilly and Company (NYSE:LLY) to $1,163 from $1,036 and kept a Buy ...

Eli Lilly and Co. announced December 9 that it would build a new $6 billion factory in Huntsville, Alabama for production of ...

The Alzheimer’s drugs market is projected to grow at a compound annual growth rate (CAGR) of approximately 20% during the ...

Target has expanded its protein and supplement sections as GLP-1 drugs like Ozempic reshape shopping habits, driving demand ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Eli Lilly has announced a price reduction for Zepbound single-dose vials, targeting improved affordability for self-pay ...

The rise of weight loss drugs such as Ozempic and Wegovy has changed the way Americans eat and shop, along with how major ...

The global drug-device combination products market is projected to experience a compound annual growth rate (CAGR) of ...